Radionuclide therapy is performed in a 12-bed inpatient ward, equipped with dedicated waste management.
The department is an international reference center and holds technology partnerships with Siemens in the area of PET, and with GE in the area of SPECT.
Through these partnerships, it is continuously equipped with latest state-of-the-art technology. Finally, once a novel tracer or technique is identified, the focus shifts toward clinical application in a pathway-based, cross-sectional manner. In essence, this focus means that the pathway targeted by the new approach is examined across organ barriers in multiple disorders, that the axis between multiple organs is studied, and/or that the effects of disease or therapy in one system is interrogated in other physiologic systems.
A recent example is the determination of the effects of anti-tumor radionuclide therapy on the biology of atherosclerotic plaques（17） .
In summary, the focus on a translational environment, the joint development of imaging alongside novel therapies, and the pathway-based cross-sectional application of molecular imaging techniques are the key principles that are pursued in cardiovascular nuclear medicine research at MHH.
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